Journal Mobile Options
Table of Contents
Vol. 69, No. 3, 2005
Issue release date: September 2005
Section title: Invited Review
Oncology 2005;69:185–201
(DOI:10.1159/000088069)

Platelet-Mimicry of Cancer Cells: Epiphenomenon with Clinical Significance

Tímár J. · Tóvári J. · Rásó E. · Mészáros L. · Bereczky B. · Lapis K.
aDepartment of Tumor Progression, National Institute of Oncology, Budapest, and b1st Institute of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Invited Review

Received: 10/6/2004
Accepted: 3/24/2005
Published online: 10/10/2005

Number of Print Pages: 17
Number of Figures: 5
Number of Tables: 3

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL

Abstract

Stem cell mimicry of cancer cells has been known for a long time and is considered to be responsible for ectopic gene expressions. The stem cell characteristics of tumor cells are shown to be involved in epithelial-mesenchymal transition and in the phenomenon of vascular mimicry. Certain cancer types acquire a geno-phenotype closely resembling the platelets and express several megakaryocytic genes (adhesion receptors αIIbβ3, thrombin receptor and PECAM/CD31 and/or platelet-type 12-LOX) able to activate the coagulation cascade or the platelets themselves. Here we define these potentials as platelet mimicry of cancer cells typical of pancreatic, breast, prostate, colorectal and urogenital cancers and melanoma. Data all support that platelet mimicry of certain cancer types is an important factor in their hematogenous dissemination and provides an attractive therapeutic target. Besides the long-available preclinical data, clinical trials have only recently provided evidence that targeting platelet mimicry of cancers is an efficient way to prevent tumor progression. The systematic discovery of the markers of platelet mimicry in various cancer types and their molecular targeting may provide new supportive therapeutic modalities for the management of the progressing disease.


  

Author Contacts

József Tímár, MD, PhD
Department of Tumor Progression
National Institute of Oncology, Ráth Gy. u. 7–9
HU–1122 Budapest (Hungary)
Tel. +36 1 224 8786, Fax +36 1 224 8706, E-Mail jtimar@oncol.hu

  

Article Information

Received: October 6, 2004
Accepted after revision: March 24, 2005
Published online: September 1, 2005
Number of Print Pages : 17
Number of Figures : 5, Number of Tables : 3, Number of References : 166

  

Publication Details

Oncology (International Journal of Cancer Research and Treatment)

Vol. 69, No. 3, Year 2005 (Cover Date: Released September 2005)

Journal Editor: Trump, D.L. (Buffalo, N.Y.)
ISSN: 0030–2414 (print), 1423–0232 (Online)

For additional information: http://www.karger.com/ocl


Article / Publication Details

First-Page Preview
Abstract of Invited Review

Received: 10/6/2004
Accepted: 3/24/2005
Published online: 10/10/2005

Number of Print Pages: 17
Number of Figures: 5
Number of Tables: 3

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.